Validating your first Shiny app for GxP: a survival guide

A short field note for teams getting ready to validate a Shiny app for GxP use.

As pharma companies move from SAS to R is well past the early-adopter phase, and a second wave of work has surfaced behind it: validating the Shiny apps that biostatistics and clinical teams have already built on top of that R stack. The SCE is being qualified. The packages are being risk-scored. The apps themselves are the next thing on the QA backlog and most teams looking around for prior art are not finding much.

Below are the patterns we keep seeing across pharma teams approaching this for the first time. None of it is theoretical. All of it is what we'd want someone to tell us before we started.

Get QA in the room before the design is locked

The technical work like writing tests, documenting reactive flows, listing dependencies is the easy part. What sinks Shiny app validation timelines is bringing QA in too late.

The pattern repeats: a biostats or clinical team builds an app, gets it working, decides it should be validated, and only then loops in QA. QA quite reasonably asks for the things QA always asks for: a Validation Plan they can sign, a risk assessment they can approve, evidence they can attach to a validation package. Because QA wasn't part of the original conversation, those asks land as scope creep. The eight-week project becomes a sixteen-week project. Nobody is wrong; the sequencing was wrong.

If you take only one thing from this post: bring QA into the conversation before you finalize scope, not after. A 30-minute conversation with your QA representative at the planning stage is worth more than any amount of documentation produced afterward. They will tell you which existing SOPs the work needs to anchor to, what signature workflow applies, and whether anyone has set precedent for validating an R-based application at your company. Without that conversation you are guessing, and your timeline is fiction.

"Validate the app against our actual study data" is the wrong ask

The instinct from a clinical or QA stakeholder who hasn't validated open-source software before is to ask for the application to be validated against the specific dataset it will be used on. This is a reasonable request for a closed system that ships with its data and a deeply unreasonable one for a Shiny app, which is a lens over data that may not even exist yet.

The right framing is a risk-based, scenario-based validation aligned with GAMP 5 (2nd edition) and FDA's CSA guidance. Define a matrix of representative scenarios that span what the app is designed to do. Different therapeutic areas, longitudinal vs. cross-sectional data, small vs. large populations, edge cases that have come up in prior analyses and validate the app against that matrix using synthetic or appropriately modified data. The validated artifact then says "this app behaves correctly across this declared scenario space," and that artifact travels with the app into new studies without re-validation each time.

Don't write a new SOP for one app

A common reflex is to draft a new SOP specifically for the Shiny app being validated. Don't. SOPs at most pharma companies take three to six months to put through governance, training, and approval and QA will rarely accept an SOP that governs a single application anyway. SOPs are written for classes of system, not instances.

The pragmatic path is to anchor to an SOP that already exists. Typically, your company's general software validation SOP, or an IT risk-based-validation SOP if one is in place and use them to write a lightweight working practice underneath it that customizes the existing SOP's process for Shiny apps. A working practice is faster to draft, faster to get accepted, and much easier to revise as you learn what actually works for this category of system. If your QA team eventually wants a dedicated SOP, the working practice becomes the basis for it.

If no suitable SOP exists at all, treat that as a separate, longer-running workstream that should be initiated in parallel, not as a blocker for validating the app you have in front of you today.

The signature workflow is the timeline killer

The column on your validation tracker that matters most for timeline is not the writing column. It's the signature column.

Validation shiny apps need signatures on the Validation Plan, on the risk assessment, on test protocols, on the Validation Summary Report. Depending on your company's process, those signatures may need to come from senior platform owners who sign for everything in the SCE. We've seen Shiny app validations where the work itself took two weeks and getting six signatures on the resulting documents took ten. Standard signature SLAs are five business days; vacations, competing priorities, and the simple fact that the person signing isn't the person who did the work mean the actual elapsed time is routinely much longer.

Two things help. First, negotiate the signature workflow before you need it, while you're still drafting the working practice. The closer the signers are to the actual work, the faster the cycle. If you can substitute a domain owner closer to the application for a senior platform owner, the SLA on every future validation improves. Second, build the signature flow into your project plan as a real, scheduled phase not as something that happens "after" the work is done. Treating signatures as wall-clock time rather than effort time is the single largest correction most first-time Shiny app validations need to make.

Make the responsibilities map explicit before you start

Most friction inside a validation project comes from ambiguity about who drafts what, who reviews what, and who signs what. Without an explicit map, every artifact becomes a small renegotiation, and the renegotiations are where weeks disappear.

Before kickoff, get one page that lists every artifact you expect to produce and assigns owners across three columns: drafted by, reviewed by, signed by. The exact ownership distribution will vary by company, what matters is that it exists, that QA has signed off on it, and that everyone involved has seen the same version. The artifacts to include at minimum: User Requirements Specification, Validation Plan, risk assessment, test protocols and evidence, working practice for Shiny validation, Validation Summary Report, and the ongoing change-management process for after release.

The change-management row matters as much as the others. A validated app is only validated until something changes. For a custom shiny app, the "something" can be a simple code change, it is important to modularize the shiny app so the level of re-validation can be minimized and this needs to be defined in writing before the first change request lands.

Reactlog is for debugging, not validation evidence

A Shiny app's reactive graph which inputs drive which outputs through which intermediate reactives is helpful because it tells the story of how a UI control reaches a calculated result. Most teams reach for reactlog to produce that view. It's the wrong tool for creating validation evidence.

reactlog instruments a running app and records the reactive graph at runtime. That makes it excellent for debugging and unsuited for validation: it requires running the app (which means credentials, data, infrastructure, side effects), it only captures the code paths that actually fired during the trace, and its graph is a single global view rather than something organized around the features a human would document.

Validation evidence should instead be per-feature, per-module, static, and developer-authorable: for each output a user can see and act on, the closed reactive subgraph that produced it, the packages used inside that subgraph, the functions called, and a slot for the developer to write the intended use. That bundle-graph plus inventory plus intended-use doc is what slots cleanly into a validation package. It can be regenerated whenever the code changes, diffed against prior versions, and reviewed without an environment.

If you're building Shiny apps that will eventually need to be validated, structuring your code so each output corresponds to a reasonably self-contained reactive subgraph and naming things so the subgraph maps to a feature a clinical user would recognize would pay off later in ways that are hard to overstate. The shape of your code determines the shape of your validation evidence. This is crucial because unlike static table generation code, shiny apps can produce outputs that can change based on app user's inputs and rich documentation of the reactive graph provides higher validation and more confidence that the output in fact the intended output the shiny app was designed to produce.

A sneak peek: what we're building

The validation evidence model described above: per-feature, static, developer-authorable is what we've been encoding into an R package called shiny.val.tools. We're not ready to release it yet, but the design is far enough along that it's worth describing.

The package treats every module in a Shiny app as a feature: a thing the user sees and acts on. For each feature, it walks the app's source code statically without running the app and emits a per-feature validation stub. The stub can be used to create the validation artifact that contains:

• A visualization of the closed reactive subgraph that produces that output, with inputs, intermediate reactives, and the output node clearly distinguished.
• The inventory of every package and function called inside that subgraph, with direct vs. transitive usage flagged.
• Warnings for things a validator should care about like ambiguous package origins, missing version pins, etc.
• A slot at the top for the developer to declare the intended use and risk classification of the feature, which the rest of the validation package can then anchor to.

Two things make this approach different from anything else we've seen in the Shiny ecosystem. First, the artifacts are regenerable: when the code changes, the package re-emits the stubs and the diff tells you exactly which features' validation evidence is now stale. Validation stops being a one-time effort and starts being something a CI pipeline can keep current. Second, the artifacts are scoped to features the QA team and the clinical user actually recognize, like the Kaplan-Meier plot, the demographics table rather than to the global reactive graph, which nobody outside the dev team can read.

We'll have more to share on shiny.val.tools in the coming weeks, including a worked example on a public Shiny apps. If you're working on Shiny app validation now and want to look at the early version, get in touch.

Where this is heading

R-in-pharma has matured to the point where the supporting infrastructure for validation is mostly in place. The R Validation Hub, pharmaverse, the R Consortium Submission Pilots, and the rhinoverse have done most of the conceptual heavy lifting. Risk-based validation is well understood. The arguments with regulators have largely been won.

What's still missing is the operational layer. The practices, tooling, and shared expectations that turn a one-off Shiny app validation into something a pharma team can do repeatedly without it consuming a quarter every time. That's where the patterns above come from, and that's where shiny.val.tools is aimed: making the validation evidence itself cheap enough to produce that the conversation can move on to the things that actually matter, like scenario design and risk assessment.

If you're navigating a Shiny app validation conversation inside your organization and want a second pair of eyes on scope, sequencing, or the QA-engagement question, we'd be glad to talk.